HOUSTON, July 27 /PRNewswire/ -- Plantacor, Inc. announced today that it has exclusively licensed the commercial rights to three preclinical cancer therapeutics from The University of Texas M. D. Anderson Cancer Center. These therapeutic drug compounds include novel liposomal formulations of Curcumin and Emodin for the treatment of multiple cancers including leukemia, and Calagualine for the treatment of leukemia and lymphoma malignancies. Plantacor has granted M. D. Anderson an equity position in the company as part of the consideration for the agreement.
"We are very excited about working with Plantacor and assisting in developing new cancer drugs that potentially may play a significant role in the lives of cancer patients," said Gabriel Lopez-Berestein, M.D., professor of bioimmunotherapy at The University of Texas M. D. Anderson Cancer Center. "Plantacor is an excellent partner to develop these therapeutic compounds as they are committed to accelerating the entrance of new drugs into the marketplace."
"This agreement is a continuation of our strategy to expand Plantacor's intellectual property portfolio in the field of safe and effective pharmaceuticals to meet the unmet needs of patients worldwide," said Robert C. Dose, chief executive officer for Plantacor. "We are very pleased that M. D. Anderson Cancer Center has entrusted Plantacor with the development of these potentially valuable therapeutic compounds."
"Plantacor is committed to making improvements in cancer treatment, not only through development and marketing anticancer therapeutic agents, but also through the utilization of technologies to minimize the adverse side effects of cancer therapy," said Gary H. Richardson, president of Plantacor. "With this license from M. D. Anderson, we are three steps closer to providing a better quality of life for cancer patients."
About Plantacor, Inc.
Plantacor, Inc. is a biopharmaceutical company engaged in the acquisition and development of natural, safe and effective therapeutic drugs, to address the unmet needs of patients worldwide. The Company's initial commercialization efforts have been focused on the preclinical development of a class of unique orally delivered tumor regressing compounds exclusively licensed from The Texas A&M University System, that are synthetic analogs of the anticancer diindolylmethane (DIM) compound derived from cruciferous vegetables. The acquisition of the rights to the three M. D. Anderson technologies broadens the depth and scope of the company's product pipeline.
CONTACT: Robert C. Dose of Plantacor, Inc., +1-979-694-8205